Scar tissue, macrophages, and endometriosis pain — and why the fibrosis may not be permanent

What that feeding looks like, at the molecular level, is the quiet construction of scar tissue. The permissive macrophage secretes transforming growth factor beta-1 — TGF-β1 — and TGF-β1 is one of the body's principal pro-fibrotic signals. It binds its receptor on resident fibroblasts and activates the SMAD2/3 signaling cascade inside them, and that cascade reprograms the fibroblast into a myofibroblast: a contractile, matrix-producing cell that lays down collagen. As more myofibroblasts appear and more collagen accumulates, the tissue stiffens into adhesions and dense fibrosis. This is the biology behind a great deal of what makes endometriosis so punishing. The adhesions tether organs to one another so that ordinary movement produces pulling and tearing sensations; the dense fibrosis distorts pelvic anatomy and is responsible, the source review notes, for much of the pain and infertility associated with the disease. The lesion, in other words, recruits the very cells meant to dismantle it and turns them into a scaffolding crew.

The macrophage's mischief does not stop at scar. Macrophage- and lesion-derived VEGF-A — vascular endothelial growth factor A — establishes the neovascular supply the implant needs to survive, sprouting new blood vessels into tissue that would otherwise starve. Meanwhile epidermal growth factor and IGF-1 sustain the proliferation of the lesion's epithelial and stromal cells. So the same immune environment that builds the scar also builds the blood supply and keeps the cells dividing. The result is an organized micro-tissue: it coordinates its own vasculature, its own stroma, and its own growth signals, all underwritten by a population of immune cells that have been talked out of doing their job. Understanding this is what shifts endometriosis from looking like a collection of misplaced cells to looking like a self-maintaining structure with a logic of its own.

The chemistry of recruitment is worth keeping in view, because it explains why the permissive state is self-sustaining rather than transient. CCL2 brings monocytes into the peritoneal cavity, and CSF-1 — colony-stimulating factor 1 — is the signal that keeps them there and pushes their differentiation toward the alternatively activated phenotype rather than the inflammatory, clearing one. This is not a one-time event. As long as the lesion and its environment keep producing those signals, fresh macrophages keep arriving and keep being polarized the wrong way, replenishing the population that supplies TGF-β1, VEGF-A and growth factors. The lesion, in effect, maintains a standing workforce. That is part of why excision alone so often fails to resolve the disease: cutting out the visible implant does not necessarily switch off the chemical environment that recruits and reprograms the immune cells, and residual signaling can re-establish the same permissive milieu around whatever lesional tissue remains. The fibrosis is downstream of a recruitment loop, and the loop is what gives it staying power.

There is a reason this matters for pain in particular, and it is worth making explicit. Endometriosis pain is often disproportionate to what imaging shows, and part of that disproportion lives in the fibrosis itself. Adhesions are not inert; they are dense, contractile, nerve-containing tissue under tension, and when organs that should slide freely past one another are instead tethered together, ordinary movement transmits force through structures that were never meant to bear it. The dense fibrosis the source review names as responsible for much of the disease's pain and infertility is therefore not a passive byproduct of inflammation but an active mechanical contributor to symptoms — and the same TGF-β1/SMAD program that builds it in the pelvis is the canonical fibrotic program studied across the body, in lung, liver, and kidney scarring. What is being described in endometriosis is not an exotic process but a familiar one playing out in an unusual place, driven by an immune cell that has been instructed to build rather than clear.

And then comes the detail that changes the stakes entirely. The stromal fibrosis built by this process is not irreversibly fixed. The source review states it directly: this fibrosis can regress under appropriate endocrine modulation, and that reversibility is not a hopeful aside but a documented point — endometriosis-related fibrosis driven by elevated TGF-β has shown evidence of reversibility under hormone-modulating regimens. That matters enormously, because scar tissue is usually imagined as the end state, the permanent residue of an injury that no longer responds to anything. If the fibrosis of endometriosis is at least partly plastic — if removing the inputs that drive it can allow the tissue to remodel back toward something looser and more normal — then the fibrotic component stops being fixed damage and becomes a potentially modifiable target. The question changes from how to live with the scar to whether the conditions that sustain it can be withdrawn.

There is a logic to where the modification might come from, too. If the macrophage's TGF-β1 is what drives the fibroblast-to-myofibroblast transition, then anything that withdraws the inflammatory and endocrine inputs sustaining that macrophage population should, over time, slow the deposition of new collagen and let the existing matrix be remodeled by the body's ordinary turnover machinery. This is not a claim that scar dissolves on its own; it is the observation that fibrosis represents a balance between laying matrix down and breaking it back down, and that the balance can shift when its drivers change. The reversibility documented under endocrine modulation is precisely what one would predict if the fibrosis were a maintained state rather than a permanent deposit — held in place by continuous signaling, and therefore in principle releasable when that signaling stops.

That reframing is what opens a research conversation, and it has to be entered carefully, because the agents studied for this part of the disease are exactly that — studied, not established. None of the compounds below has controlled human efficacy data in endometriosis. They are mechanistically coherent and supported by preclinical work or by data from other tissues, and their use in endometriosis is investigational and not an approved indication. With that boundary drawn, three are worth understanding, because each engages a different point in the macrophage-and-fibrosis story.

It is worth being clear about what these three agents are each trying to do, because they attack the fibrosis story at genuinely different points and the distinction governs how plausible each is. One aims at the cause — the misdirected immune cell that issues the pro-fibrotic instruction in the first place. One aims at the consequence — the deposited matrix itself, trying to remodel scar that already exists. And one aims at repair more broadly, with the complication that its repair mechanism overlaps with the lesion's own survival mechanism. Targeting the cause, the consequence, and the repair process are not interchangeable strategies; a clearance-restoring approach might slow new fibrosis without touching old adhesions, while a matrix-remodeling approach might soften existing scar without addressing why it formed. Holding those apart is part of reading the evidence honestly, because an agent's coherence against one point in the story says nothing about its effect at another.

Thymosin α-1 goes after the macrophage's mistaken identity. It is a 28-amino-acid thymic peptide that acts principally as an agonist of the Toll-like receptors TLR9 and TLR2 on dendritic cells and monocytes. Through TLR signaling it drives dendritic-cell maturation, nudges naïve T cells toward a cell-mediated Th1 phenotype, and enhances cytotoxic T-cell and natural-killer activity while supporting regulatory balance — the net effect being a restoration of competent immune surveillance. The relevance to endometriosis is direct: peritoneal immunity in the disease is skewed toward exactly the permissive, M2-like state that nourishes ectopic tissue rather than clearing it. The rationale for thymosin α-1 is re-education of that milieu — repolarizing the macrophages and reactivating clearance pathways so that the implant loses both its immune tolerance and the cytokine and growth-factor supply the macrophages provide. Thymosin α-1 carries an established human safety record; it is approved in several countries as thymalfasin for chronic hepatitis B and C and as an adjuvant in sepsis and some cancers. But it has not been trialed in endometriosis, and that approval elsewhere is not approval here.

GHK-Cu works on the scar itself rather than the cell that builds it. It is the copper(II)-binding tripeptide glycyl-L-histidyl-L-lysine, and its principal action is to reshape the extracellular matrix. By delivering copper and acting as a transcriptional modulator, GHK-Cu upregulates decorin, reorganizes collagen and elastin, and rebalances the matrix metalloproteinases against their tissue inhibitors, the MMP/TIMP ratio that governs whether tissue is being broken down or built up. The thrust of that activity is to favor orderly remodeling over disorganized fibrosis, and GHK-Cu additionally modulates TGF-β-associated fibrogenic signaling — the same pathway, recall, that produces endometriotic adhesions in the first place. The plausible endometriosis rationale is anti-fibrotic remodeling of established scar and adhesion tissue. The honest qualifier is that the evidence base is dermatologic and cell-based: GHK-Cu has been characterized in skin and connective tissue, and its systemic dosing and effects in pelvic tissue are simply uncharacterized in living systems. Its pelvic effects are, at present, an extrapolation.

The MMP/TIMP balance GHK-Cu is said to influence deserves a moment, because it is the molecular hinge on which reversibility turns. Matrix metalloproteinases are the enzymes that break extracellular matrix down; their tissue inhibitors, the TIMPs, hold them in check. When the balance tips toward the inhibitors, matrix accumulates and tissue fibroses; when it tips back toward the metalloproteinases, accumulated matrix can be degraded and remodeled. This is the same balance, in molecular terms, that the reversibility of endometriosis fibrosis depends on — for scar to regress, the breakdown side of the equation has to be allowed to operate. An agent that rebalances MMP against TIMP is therefore, in principle, acting on exactly the lever that determines whether fibrosis is being laid down or cleared. Whether GHK-Cu does this usefully in pelvic tissue, at a tolerable systemic dose, in a living person with endometriosis, is unknown. But the mechanism it is reaching for is the right one for the problem, which is why it appears in the research conversation at all rather than because anyone has shown it works here.

Thymosin α-1's safety record elsewhere deserves a fair hearing alongside the caveat, because it changes the character of the uncertainty. With a compound that has never been given to humans, two questions are open at once: does it work, and is it safe? With thymosin α-1, approved as thymalfasin in several countries and used in hepatitis and as a sepsis and oncology adjunct, the second question has a substantial body of human experience behind it even though the first, in endometriosis, has none. That does not make it effective for this disease — an established safety profile in hepatitis tells you nothing about whether macrophage re-education has any effect on endometriotic implants — but it does mean that, were the disease-specific testing to be done, it would not be starting from zero on tolerability. The agent's situation is therefore unusual: a coherent mechanism, a real human safety history, and a complete absence of endometriosis efficacy data, all at once. The honest reading keeps those three facts distinct rather than letting the safety record stand in for an efficacy claim it cannot support.

BPC-157 is where the analysis has to slow down and be most careful, because its mechanism cuts both ways. The synthetic 15-amino-acid peptide is best characterized for upregulating the VEGFR2–eNOS–nitric oxide pathway in endothelial cells, which accelerates angiogenesis and restores blood flow, alongside FAK–paxillin signaling that drives cell migration and granulation-tissue formation. In rodent models of gut, tendon and ligament injury this produces faster restoration of tissue integrity and more organized collagen architecture — healthy remodeling rather than disorganized scar. The tension for endometriosis is explicit and unavoidable: the very VEGFR2-driven angiogenesis that repairs injured tissue is the same process a lesion exploits to build its own neovascular supply. The repair machinery and the disease machinery overlap. BPC-157's net effect on implants is therefore genuinely uncertain — it could in principle help remodel scar, or it could feed the lesion's blood supply, and there is no basis for assuming the favorable outcome. The source review is unambiguous that this must be tested directly rather than assumed beneficial. BPC-157 is not an approved drug and has no human endometriosis data, and in this disease that uncertainty is not a footnote; it is the headline.

Set these together and a picture emerges that is more hopeful than the word fibrosis usually allows, and more demanding than enthusiasm usually concedes. The scar tissue at the heart of so much endometriosis pain is not laid down by accident; it is built deliberately by immune cells that have been redirected, through TGF-β1 and SMAD signaling, into making collagen instead of clearing tissue. And because the inputs that drive it can in principle be withdrawn, the scar is not necessarily the final word. That single fact — that the fibrosis may be modifiable rather than fixed — is what makes the macrophage and its TGF-β1 worth studying as targets at all, because there would be little point aiming at permanent damage. The agents that aim there remain investigational, and one of them carries a real and unresolved tension about whether it would help or harm. The implication is not that the scar can be undone today. It is that endometriosis-associated fibrosis behaves less like a fixed end state and more like an ongoing process, and a process, unlike a scar, is something a future therapy might be able to interrupt — under the guidance of a prescribing provider, and only once the testing the biology demands has actually been done.